Midcareer Investigator Award in Patient-Oriented Research (Parent K24)

以患者为导向的研究中的职业生涯中期研究员奖（家长 K24）

基本信息

批准号：
9561374
负责人：
Mark Sebastian Sulkowski
金额：
$ 12.2万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-04-15 至 2023-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9561374
关键词：
AIDS clinical trial group Academy Acute Hepatitis C African American Alcohol or Other Drugs use Alcoholic steatohepatitis Award Cardiovascular system Caring Cells Centers for Disease Control and Prevention (U.S.)Cessation of life Chronic Hepatitis C Clinic Clinical Clinical Investigator Clinical Management Clinical Research Collaborations Communicable Diseases Communities Comparative Study Data Development Disease Doctor of Medicine Drug usage Effectiveness Elderly Epidemic Funding Genotype Goals HIV HIV Infections HIV/HCV Health Hepatitis Hepatitis B Virus Hepatitis C Hepatitis C Incidence Hepatitis C Therapy Hepatitis C Transmission Hepatitis C co-infection Hepatitis C virus Hepatocyte Immune Immune response Incentives Individual Infection Injecting drug user Injections Intervention Kidney Kidney Transplantation Lasers Link Liver Liver Failure Liver diseases Malignant Neoplasms Medicine Mentors Mentorship Microdissection Mid-Career Clinical Scientist Award (K24)Midcareer Investigator Award in Patient-Oriented Research Network-based Opioid Osteomyelitis Outcome Parents Participant Persons Pilot Projects Population Prevalence Prevention Preventive Intervention Publications Randomized Reporting Research Research Personnel Resources Risk Role Science Social Network Suboxone Substance abuse problem Testing Time Tissues Toxicology Training Translations United States United States National Institutes of Health Universities Urine Virus Diseases Work addiction barrier to care base bone cardiovascular infection career co-infection cost curative treatments disorder risk financial incentive indexing innovation intrahepatic kidney infection liver transplantation medical schools member mortality non-alcoholic nonalcoholic steatohepatitis novel opioid injection opioid treatment program opioid use disorder pathogen patient population peer coaching peer support prevent professor programs recruit treatment as usual young adult

项目摘要

The current proposal is a competitive renewal of a K24 Midcareer Investigator Award in Patient- oriented research for Mark S. Sulkowski, MD of the Johns Hopkins University School of Medicine. Dr. Sulkowski is an infectious disease-trained clinical investigator at Johns Hopkins University where he is a Professor of Medicine and directs a highly productive clinical research program focused on the intersection of HIV, hepatitis C virus (HCV), and substance use. His research is supported by an NIH R01 and the NIH-funded AIDS Clinical Trials Group (ACTG); he serves as the Chair of the ACTG Hepatitis Transformative Sciences Group. During his time at Johns Hopkins, he has made substantial scientific contributions to the development of revolutionary HCV treatments. His work has also significantly advanced the clinical management of HCV disease in persons living with HIV infection. Current HCV therapies can cure more than 95% of individuals who are successfully linked to care and initiate treatment including individuals with HIV coinfection and those who use drugs. However, in 2013, the annual HCV-related mortality surpassed the combined number of deaths from 60 other infections reported to the Centers for Disease Control, including HIV. While HCV-related deaths are most common in older adults with long-standing HCV, the United States has also witnessed the resurgence of new HCV infections in young adults as the result of the injection opiate epidemic. In 2017, the National Academy of Medicine concluded that treating all persons with chronic HCV would reduce new infections by 90% and HCV-related deaths by 65% by 2030. To achieve this ambitious goal, strategies to prevent and cure HCV in persons who inject drugs are urgently needed. Renewal of this K24 is critical to Dr. Sulkowski's plan to investigate such strategies. Project aims include new collaborative research to evaluate the role of injection networks in HCV treatment and prevention and to assess the feasibility of HCV clinic-based buprenorphine-naloxone to increase concurrent treatment of HCV and opiate use disorders. For progress to be made toward achieving the Academy's goals, young clinical investigators are also needed. During the initial K24 period, Dr. Sulkowski had over 67 publications; the majority of which included young investigators who are pursuing careers in academic research. Renewal of this K24 award is critical to his desire to continue to mentor junior researchers in the key fields of HIV and HCV and to continue to evolve his research through new training in substance abuse research. The protected time afforded by this award is essential to Dr. Sulkowski achieving these goals.

目前的提案是 K24 职业生涯中期研究者奖的竞争性续展——患者- 约翰·霍普金斯大学医学院医学博士 Mark S. Sulkowski 的定向研究。 Sulkowski 博士是约翰·霍普金斯大学接受过传染病培训的临床研究员他是一名医学教授，负责指导一个高效的临床研究项目重点关注艾滋病毒、丙型肝炎病毒 (HCV) 和药物滥用的交叉点。他的研究是由 NIH R01 和 NIH 资助的艾滋病临床试验小组 (ACTG) 支持；他担任 ACTG 肝炎转型科学小组主席。在约翰斯任职期间霍普金斯博士，他为革命性丙型肝炎的发展做出了重大科学贡献治疗。他的工作还显着推进了 HCV 疾病的临床管理艾滋病毒感染者。目前的 HCV 疗法可以治愈 95% 以上的患者成功获得护理并开始治疗的人，包括艾滋病毒合并感染者以及那些使用毒品的人。然而，2013年，每年HCV相关死亡率超过了向疾病控制中心报告的 60 起其他感染的死亡人数合计，包括艾滋病毒。虽然丙型肝炎相关死亡最常见于长期患有丙型肝炎的老年人。 HCV，美国也见证了青壮年新增HCV感染的死灰复燃注射阿片类药物流行的结果。 2017年，美国国家医学院得出的结论是，治疗所有慢性 HCV 患者可将新发感染减少 90%，并且到 2030 年，HCV 相关死亡人数将减少 65%。为了实现这一雄心勃勃的目标，需要制定预防和预防策略迫切需要治愈注射吸毒者的丙肝病毒。 K24 的更新对于 Dr. 来说至关重要。苏尔科斯基计划研究此类策略。项目目标包括新的合作研究评估注射网络在 HCV 治疗和预防中的作用并评估基于 HCV 临床的丁丙诺啡-纳洛酮增加 HCV 同步治疗的可行性和阿片类药物使用障碍。为了在实现学院目标方面取得进展，年轻的还需要临床研究人员。在最初的 K24 期间，Sulkowski 博士有超过 67 出版物；其中大多数包括正在从事职业生涯的年轻研究人员学术研究。续订 K24 奖项对于他继续指导青少年的愿望至关重要 HIV 和 HCV 关键领域的研究人员，并通过新的方法继续发展他的研究药物滥用研究培训。该奖项提供的受保护时间对于 Sulkowski 博士实现了这些目标。